Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy

Glioblastoma (GBM) is an aggressive and lethal malignancy of the central nervous system with a median survival rate of 15 months. We investigated the combined anticancer effects of nerve growth factor (NGF), cathelicidin (LL-37), and protegrin-1 (PG-1) with chemotherapy (temozolomide, doxorubicin, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chernov, Alexandr, Kudryavtsev, Igor, Komlev, Aleksei, Alaverdian, Diana, Tsapieva, Anna, Galimova, Elvira, Shamova, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669874/
https://www.ncbi.nlm.nih.gov/pubmed/38002009
http://dx.doi.org/10.3390/biomedicines11113009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669874/
https://www.ncbi.nlm.nih.gov/pubmed/38002009
http://dx.doi.org/10.3390/biomedicines11113009

Ejemplares similares